AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11004038 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (15-20 mL of 3% 2-chloroprocaine)
Number of subjects: 48
Study 11004038 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (75 mg of subarachnoid procaine with 20 microg fentanyl)
Number of subjects: 48
Study 8837407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis during recall
Number of subjects: 82
Study 8837407 — intervention group
Group type: COMPARATOR
Intervention: Waking during recall
Number of subjects: 82
Study 8837407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 82
Study 8837407 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization ability
Number of subjects: 82
Study 8837407 — intervention group
Group type: EXPERIMENTAL
Intervention: High imagery recall
Number of subjects: 82
Study 1330962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg for three days)
Number of subjects: 11
Study 1330962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6383049 — intervention group
Group type: EXPERIMENTAL
Intervention: Full physical activity immediately after hospital discharge
Number of subjects: 108
Study 6383049 — intervention group
Group type: COMPARATOR
Intervention: Strictly forbidden physical activities for six weeks
Number of subjects: 108
Study 31842771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 40
Study 31842771 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 5% gel
Number of subjects: 40
Study 28994035 — intervention group
Group type: EXPERIMENTAL
Intervention: SurvivorCHESS eHealth intervention
Number of subjects: 284
Study 28994035 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study 26987963 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional rehabilitation therapies
Number of subjects: 60
Study 26987963 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapies
Number of subjects: 60
Study 24582111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 54
Study 24582111 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 54
Study 22486133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus midazolam
Number of subjects: 36
Study 22486133 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus midazolam
Number of subjects: 36
Study 20451192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined approach of diagnostic hysteroscopy and endometrial sampling during oral contraceptive pill treatment followed by ultrashort GnRH‐ag/GnRH‐ant protocol
Number of subjects: 19
Study 20451192 — intervention group
Group type: COMPARATOR
Intervention: Previous failed IVF attempt
Number of subjects: 19
Study 18630768 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 30
Study 18630768 — intervention group
Group type: COMPARATOR
Intervention: Non BIS (control group)
Number of subjects: 30
Study 16138560 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (2 to 12 mg daily)
Number of subjects: 2048
Study 16138560 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs
Number of subjects: 2048
Study 11809430 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (acetylsalicylic acid [ASA], 1, 3, and 10 mg/min)
Number of subjects: 71
Study 10640079 — intervention group
Group type: EXPERIMENTAL
Intervention: StatLock i.v. securement device
Number of subjects: 2
Study 10640079 — intervention group
Group type: COMPARATOR
Intervention: Standard securement technique
Number of subjects: 2
Study 8552739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory focus with procedural information
Number of subjects: 303
Study 8552739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory focus without procedural information
Number of subjects: 303
Study 8552739 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural information
Number of subjects: 303
Study 8552739 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 303
Study 2014890 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinised bupivacaine with adrenaline 1:200,000 (pH = 6.9)
Number of subjects: 20
Study 2014890 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with adrenaline 1:200,000 (pH = 4.1)
Number of subjects: 20
Study 2014890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Alkalinised and non-alkalinised bupivacaine)
Number of subjects: 20
Study 6294796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (20 mg/kg IV every 6 hr)
Number of subjects: 112
Study 6294796 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus Clindamycin (1 mg/kg gentamicin IV every 8 hr plus 5 mg/kg clindamycin IV every 6 hr)
Number of subjects: 112
Study 31063870 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Implementation Intervention (access to RxWL)
Number of subjects: 60
Study 31063870 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Intervention (access to RxWL with additional training and support)
Number of subjects: 60
Study 31063870 — intervention group
Group type: COMPARATOR
Intervention: Monthly Lessons (within RxWL patient platform)
Number of subjects: 60
Study 31063870 — intervention group
Group type: COMPARATOR
Intervention: Refresher Courses (within RxWL patient platform)
Number of subjects: 60
Study 31063870 — intervention group
Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 60
Study 28504031 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.25% desoximetasone spray
Number of subjects: 120
Study 28504031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state for isoniazid
Number of subjects: 20
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state for isoniazid
Number of subjects: 20
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state for rifampicin
Number of subjects: 20
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state for rifampicin
Number of subjects: 20
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state for ethambutol
Number of subjects: 20
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state for ethambutol
Number of subjects: 20
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state for pyrazinamide
Number of subjects: 20
Study 26661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state for pyrazinamide
Number of subjects: 20
Study 22928741 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 100
Study 22928741 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative PET review
Number of subjects: 100
Study 22928741 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis with SUV thresholds
Number of subjects: 100
Study 21610189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheltered workshops
Number of subjects: 430
Study 21610189 — intervention group
Group type: COMPARATOR
Intervention: Not in sheltered workshops
Number of subjects: 430
Study 21175030 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (3M Unitek - small base)
Number of subjects: 80
Study 21175030 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (American Orthodontics)
Number of subjects: 80
Study 21175030 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (Hangzhou Dentop)
Number of subjects: 80
Study 21175030 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (3M Unitek - large base)
Number of subjects: 80
Study 21175030 — intervention group
Group type: COMPARATOR
Intervention: Groups A and B
Number of subjects: 80
Study 21175030 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups except A and B
Number of subjects: 80
Study 21175030 — intervention group
Group type: EXPERIMENTAL
Intervention: All buccal tubes
Number of subjects: 80
Study 17982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab in conjunction with peptide vaccinations
Number of subjects: 139
Study 17982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-patient dose escalation of ipilimumab
Number of subjects: 139
Study 17982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of immune-related adverse events (IRAE)
Number of subjects: 139
Study 17982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior therapy with IFNalpha-2b
Number of subjects: 139
Study 17982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior high-dose interleukin-2
Number of subjects: 139
Study 17982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of high-dose steroids for treatment-related toxicities
Number of subjects: 139
Study 15525928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ege's test for medial meniscal lesions
Number of subjects: 150
Study 15525928 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Line Tenderness (JLT) for medial meniscal lesions
Number of subjects: 150
Study 15525928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ege's test for lateral meniscal tears
Number of subjects: 150
Study 15525928 — intervention group
Group type: EXPERIMENTAL
Intervention: McMurray's test for medial meniscal lesions
Number of subjects: 150
Study 15525928 — intervention group
Group type: EXPERIMENTAL
Intervention: McMurray's test for lateral meniscal tears
Number of subjects: 150
Study 15525928 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Line Tenderness (JLT) for lateral meniscal tears
Number of subjects: 150
Study 15525928 — intervention group
Group type: COMPARATOR
Intervention: All tests (Ege's, McMurray's, JLT)
Number of subjects: 150
Study 11549530 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta(2)-agonists (formoterol) with inhaled corticosteroids
Number of subjects: 94
Study 11549530 — intervention group
Group type: COMPARATOR
Intervention: Short-acting beta(2)-agonists (salbutamol)
Number of subjects: 94
Study 11549530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 9740164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose formulation of epoetin alfa
Number of subjects: 28
Study 9740164 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose formulation of epoetin alfa
Number of subjects: 28
Study 9740164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 28
Study 8113548 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day for 2 weeks)
Number of subjects: 10
Study 8113548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3123540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 20 mg
Number of subjects: 27
Study 3123540 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.1 mg/kg up to 4 mg
Number of subjects: 27
Study 3123540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cromolyn and terbutaline
Number of subjects: 27
Study 30832548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 185
Study 30832548 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen
Number of subjects: 185
Study 29231470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion with moxa stick applied to Guanyuan (CV 4), Zusanli (ST 36) and Sanyinjiao (SP 6), once every other day for 2 months
Number of subjects: 72
Study 29231470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion group
Number of subjects: 72
Study 29231470 — intervention group
Group type: COMPARATOR
Intervention: Medication group (yupingfeng granules prescribed for oral administration, three times a day for 2 months)
Number of subjects: 72
Study 26233501 — intervention group
Group type: EXPERIMENTAL
Intervention: TH/lidocaine (LD; n = 30) with TH 20 mg/ml and LD 2%
Number of subjects: 60
Study 26233501 — intervention group
Group type: COMPARATOR
Intervention: LD (n = 30)
Number of subjects: 60
Study 23876561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 40
Study 23876561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21641819 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of remifentanil (target: 7 ng/mL)
Number of subjects: 40
Study 21641819 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) of remifentanil (0.3 μg/kg/min)
Number of subjects: 40
Study 20023610 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed information supplied in the form of anticipatory guidance (3 rounds)
Number of subjects: 649
Study 20023610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 649
Study 15287307 — intervention group
Group type: EXPERIMENTAL
Intervention: LactoSorb (resorbable osteosynthesis material)
Number of subjects: 60
Study 15287307 — intervention group
Group type: COMPARATOR
Intervention: Titanium osteosynthesis
Number of subjects: 60
Study 10399633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.2‐mmol/kg intravenous bolus)
Number of subjects: 0
Study 8570858 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltorphin (DT)
Number of subjects: 0
Study 8570858 — intervention group
Group type: COMPARATOR
Intervention: Arginine (ARG)
Number of subjects: 0
Study 8570858 — intervention group
Group type: COMPARATOR
Intervention: Galanin (GAL)
Number of subjects: 0
Study 2246974 — intervention group
Group type: EXPERIMENTAL
Intervention: met‐hGH (16.0 mg/wk of Protropin)
Number of subjects: 7
Study 2246974 — intervention group
Group type: COMPARATOR
Intervention: placebo (bacteriostatic water)
Number of subjects: 7
Study 6258116 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO I and ACO II protocols
Number of subjects: 94
Study 6258116 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO II protocol (maintenance therapy after aggressive induction treatment)
Number of subjects: 94
Study 6258116 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 94
Study 31090458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 (2.5×10^9 cfu/capsule)
Number of subjects: 114
Study 31090458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis B94 (5×10^9 cfu/capsule)
Number of subjects: 114
Study 31090458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 27918846 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy food consumption (2 daily servings)
Number of subjects: 316
Study 27918846 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet
Number of subjects: 316
Study 27918846 — intervention group
Group type: COMPARATOR
Intervention: Soy food consumption
Number of subjects: 316
Study 26567264 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism spectrum disorder in larger classrooms
Number of subjects: 334
Study 26567264 — intervention group
Group type: COMPARATOR
Intervention: Typically developing boys in larger classrooms
Number of subjects: 334
Study 26567264 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism spectrum disorder
Number of subjects: 334
Study 25012265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) only
Number of subjects: 220
Study 25012265 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC plus enoxaparin
Number of subjects: 220
Study 25012265 — intervention group
Group type: COMPARATOR
Intervention: IPC only
Number of subjects: 220
Study 22873207 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 60
Study 22873207 — intervention group
Group type: COMPARATOR
Intervention: Watson‐Jones Approach (WJA)
Number of subjects: 60
Study 19617863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 1018
Study 19617863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study 17886253 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 10 mg per day
Number of subjects: 809
Study 17886253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study 15282985 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 30 ml of ropivacaine 7.5 mg/ml
Number of subjects: 80
Study 15282985 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment only (Paracetamol and tramadol)
Number of subjects: 80
Study 15282985 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 80
Study 11337303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, and 100 mg)
Number of subjects: 247
Study 11337303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 9849708 — intervention group
Group type: EXPERIMENTAL
Intervention: Open vaginal cuff technique
Number of subjects: 100
Study 9849708 — intervention group
Group type: COMPARATOR
Intervention: Closed vaginal cuff technique
Number of subjects: 100
Study 9849708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study 8003642 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg every morning
Number of subjects: 250
Study 8003642 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg every morning and at bedtime
Number of subjects: 250
Study 8003642 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 250
Study 2583918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 655
Study 2583918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10, 20, 40 mg
Number of subjects: 655
Study 2583918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 31386273 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 125 mg daily
Number of subjects: 61
Study 31386273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30629330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (iCT)
Number of subjects: 29
Study 30629330 — intervention group
Group type: COMPARATOR
Intervention: Postoperative MRI
Number of subjects: 29
Study 30629330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (iCT) and Postoperative MRI
Number of subjects: 29
Study 28357504 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum (two doses)
Number of subjects: 137
Study 28357504 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum (four doses)
Number of subjects: 137
Study 28357504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 25998572 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release aspirin (ER-ASA)
Number of subjects: 50
Study 25998572 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release aspirin (IR-ASA)
Number of subjects: 50
Study 24147073 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Number of subjects: 81
Study 24147073 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study 21859401 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2080 mg daily for 10 weeks)
Number of subjects: 34
Study 21859401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19670623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bithermal test before PRM
Number of subjects: 96
Study 19670623 — intervention group
Group type: COMPARATOR
Intervention: Bithermal test after PRM
Number of subjects: 96
Study 18085141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear point taping and pressing therapy combined with acupoint-injection
Number of subjects: 116
Study 18085141 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine (medication group)
Number of subjects: 116
Study 15181487 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg thrice daily
Number of subjects: 55
Study 15181487 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 800 mg 5 times daily
Number of subjects: 55
Study 15181487 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 55
Study 15181487 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 55
Study 12177566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 159
Study 12177566 — intervention group
Group type: COMPARATOR
Intervention: Basic Case Management (BCM)
Number of subjects: 159
Study 9716311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 37
Study 9716311 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 37
Study 9716311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8083368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg t.i.d.) during high salt diet
Number of subjects: 19
Study 8083368 — intervention group
Group type: COMPARATOR
Intervention: Placebo during high salt diet
Number of subjects: 19
Study 8083368 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet (UNaV > 200 meq/d)
Number of subjects: 19
Study 8083368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet (UNaV < 50 meq/d)
Number of subjects: 19
Study 2574052 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg once daily)
Number of subjects: 0
Study 2574052 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg once daily)
Number of subjects: 0
Study 2574052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15825310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 10
Study 15825310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 10
Study 15825310 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 10
Study 31943293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg
Number of subjects: 289
Study 31943293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 31228136 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-End Anastomosis (SEA)
Number of subjects: 336
Study 31228136 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon J-Pouch (CJP)
Number of subjects: 336